HOUSTON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform ...
We recently published a list of 10 Micro-, Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where Plus Therapeutics Inc. (NASDAQ:PSTV) stands against other ...
Shares of Plus Therapeutics, Inc. (PSTV Quick Quote PSTV - Free Report) were up a whopping 311.4% on March 6 after the company announced that the FDA has granted an Orphan Drug Designation (“ODD”) to ...
Hosted on MSN
Plus (PSTV) Upgraded to Buy: Here's Why
Plus Therapeutics (PSTV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
・Plus has appointed Eric J. Daniels as its chief development officer, effective April 20. ・The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma ...
Plus, Therapeutics, Inc. (NASDAQ:PSTV) shares are trading higher during the premarket session on Friday. The company reported the publication of Phase 1 clinical trial results for Rhenium (186Re) ...
Plus Therapeutics (NASDAQ:PSTV) stock is climbing higher on Monday after the company revealed a stock buyback program. According to a press release from the company, its board of directors approved ...
Plus Therapeutics Inc (NASDAQ:PSTV) shares are trading higher by 244% to $1.75 during Thursday’s session after the company announced that the FDA accepted the name REYOBIQ for the company’s lead asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results